RYTM News and Press, Rhythm Pharmaceuticals Inc. From 05/05/21

BOSTON, May 05, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the treatment paradigm for people living with rare genetic diseases of obesity, today announced that David Meeker, M.D., Chair, Presid...

Rhythm Pharmaceuticals (RYTM): Q1 GAAP EPS of $0.90.Revenue of $0.04M.Rhythm expects that its existing cash, cash equivalents and short-term investments as of March 31, 2021, will be sufficient to fund its operating expenses and capital expenditure requirements into at least the second half o...

-- First U.S. commercial sales of IMCIVREE™ (setmelanotide) completed late in first quarter – -- Late-breaking data presentations at ENDO 2021 demonstrated continued weight loss with setmelanotide at up to nine months in HET obesity, as well as weight loss data in ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Insiders are people who have access to private information about a company and can do something called insider buying . They include a company’s senior management, members of the board of directors and other importa...

BOSTON, April 07, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that David Meeker, M.D., Chair, President and Chief Ex...

Gainers: [[GTAT]] +49%. [[PFIN]] +13.6%. [[RYTM]] +5.6%. [[WING]] +3.8%. [[CLNE]] +3.1%.Losers: [[DISCB]] -10.9%. [[WMG]] -8.9%. [[TLS]] -7.7%. [[TXG]] -7.1%. [[BCEL]] -6.9%. For further details see: GTAT, PFIN, DISCB and BCEL among after-hours movers

Rhythm Pharmaceuticals (RYTM), over the weekend, posted data from its mid and late stage studies of anti-obesity medication setmelanotide at the 103rd Annual Meeting and Expo of the Endocrine Society ((ENDO 2021)).The presentations included data from a Phase 2 study of setmelanotide...

-- Responders with HET obesity achieved mean weight loss of greater than 12 percent at nine months on setmelanotide therapy -- -- Additional poster presentations include Phase 3 data in Bardet-Biedl and Alström syndromes and analyses of adverse events in Phase 2 and Pha...

BOSTON, March 09, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that three late-breaking abstracts have been accepted ...

Rhythm Pharmaceuticals (RYTM): Q4 GAAP EPS of -$0.79.Cash, cash equivalents and short-term investments of $172.8M.Press Release For further details see: Rhythm Pharmaceuticals reports Q4 results